Back to top
more

Oncobiologics (OTLK)

(Delayed Data from NSDQ)

$8.19 USD

8.19
150,569

-0.01 (-0.12%)

Updated Apr 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy

Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.

Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More

Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.

Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate

Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.

Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?

Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Oncobiologics, Inc. (OTLK) delivered earnings and revenue surprises of -83.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Oncobiologics, Inc. (OTLK) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Oncobiologics, Inc. (OTLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Sweta Killa headshot

Hottest Wall Street Stories: What's Up, What's Down

Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.